StockNews.AI
DMAAU
StockNews.AI
176 days

Drugs Made in America Acquisition Corp. Announces Advisory Team

1. DMAAU forms advisory team to pursue US pharmaceutical acquisition opportunities. 2. Team led by CEO Lynn Stockwell with veterans from CVS and BMW. 3. Focus is on establishing resilient, domestic drug manufacturing and distribution. 4. Aims to mitigate national security risks and enhance supply chain reliability.

7m saved
Insight
Article

FAQ

Why Bullish?

The advisory team formation signals a proactive strategy towards domestic acquisitions, potentially boosting DMAAU's long‐term growth. Similar moves in SPACs, when strategically executed (e.g., CVS restructuring), have historically led to favorable market reactions.

How important is it?

This announcement directly relates to DMAAU's core strategy of domestic production and may drive strategic acquisitions, though execution risks remain. Its forward-looking nature and emphasis on supply chain resilience make it critical for long-term investor confidence.

Why Long Term?

The acquisition strategy and onshoring production impacts will take time to materialize, aligning benefits with long-term market trends. Historical M&A cases in pharmaceutical sectors typically yield significant value over an extended period.

Related Companies

CVSBMW
Fort Lauderdale, FL, Feb. 24, 2025 (GLOBE NEWSWIRE) --  Drugs Made in America Acquisition Corp. (Nasdaq: DMAAU), (the “Company”) today announced the formation of an advisory team to lead its effort towards acquiring a well-managed, revenue generating business for the foundation and development of “End to End production, manufacturing and distribution, for the Drugs Made In America Platform”.  Under the direction of Lynn Stockwell, Chief Executive Officer of DMAAU, the advisory team will proactively pursue the deliverable of a business or combinations that seeks to become a new competitive cost producer of drugs made in America. Onboarding production back to the USA creates jobs, mitigates national security risks and will ensure the American people will have clean, pure, cost-efficient medications through a resilient supply chain made in America. The advisory team includes Charles C. Conaway who is chairman of The Sabre group, a private capital business which has operated, acquired & originated a variety of businesses in the health, consumer and other segments.   Mr. Conaway has led and served on the Board of a variety of organizations, including Fortune 100 companies as President of CVS Corporation, where he led the successful restructuring to create CVS as a stand-alone public company.  Mr. Conaway was one of the lead architects in transforming CVS from a large retailer to one of largest health care companies in the U.S. The team also includes Paul J. Mastronardi and Edward A. Robinson. Mr. Mastronardi is a third-generation greenhouse grower and distributor in the North American market. He was recognized as a Top 10 Under 40 honoree by Greenhouse Canada in 2017 and as a Top 40 Under 40 honoree by Produce Business in 2024. Paul also serves on multiple boards across various industries and brings extensive experience in developing businesses. Mr. Robinson is the former Chief Executive Officer of BMW Financial Services N.A. He was responsible for the America’s Region, which included BMW Bank, an Industrial Loan Corporation in Salt Lake City, Utah. Since retiring from BMW, Mr. Robinson has acted as a consultant on a wide range of businesses including public and private entities. The team will leverage resources and networks for efficient outreach to commence immediately. The effort will be focused on creating proprietary transaction opportunities. The Company believe personal relationships built over time are critical not just in generating transaction opportunities, but also in consummating a business combination. About Drugs Made In America Acquisition Corp. The Company is a blank check company incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. It has not selected any specific business combination target and has not, nor has anyone on its behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination. While the Company may pursue a business combination target in any business, industry or geographical location, it intends to focus its search for businesses in the pharmaceutical industry. The Company believes that it is possible to mitigate risks in the U.S. medical supply chain by investing in companies that will reduce America’s overreliance on production of pharmaceuticals from concentrated geographic regions through investments in strategic on-shoring of advanced domestic manufacturing technologies for critical drugs. Contact Information Drugs Made In America Acquisition Corp.1 East Broward Boulevard, Suite 700Fort Lauderdale, FL 33301 Lynn Stockwell Chief Executive Officer and Executive ChairEmail: lynn@dmaacorp.comPhone: (954) 870-3099 Forward-Looking Statements This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. No assurance can be given that the offering discussed above will be completed on the terms described, or at all. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related preliminary prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC's website, www.sec.gov.

Related News